Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CERo Therapeutics Holdings, Inc. stock logo
CERO
CERo Therapeutics
$0.00
+2.1%
$0.01
$0.00
▼
$0.14
$351K0.27636,618 shs627,610 shs
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
$3.28
+13.5%
$4.96
$1.90
▼
$10.54
$4.79M3.21424,504 shs17,015 shs
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
$0.02
-8.0%
$0.85
$0.02
▼
$10.99
$363K1.1624.32 million shs121.84 million shs
Petros Pharmaceuticals, Inc. stock logo
PTPI
Petros Pharmaceuticals
$0.00
+15.4%
$0.00
$0.00
▼
$0.02
$93K2.04117,487 shs19,830 shs
10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CERo Therapeutics Holdings, Inc. stock logo
CERO
CERo Therapeutics
0.00%+41.18%-20.00%-57.52%-94.61%
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
0.00%-27.51%-38.95%-44.61%-56.65%
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
0.00%-70.86%-95.90%-99.12%-99.72%
Petros Pharmaceuticals, Inc. stock logo
PTPI
Petros Pharmaceuticals
0.00%-21.21%-3.70%-3.70%-84.34%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CERo Therapeutics Holdings, Inc. stock logo
CERO
CERo Therapeutics
$0.00
+2.1%
$0.01
$0.00
▼
$0.14
$351K0.27636,618 shs627,610 shs
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
$3.28
+13.5%
$4.96
$1.90
▼
$10.54
$4.79M3.21424,504 shs17,015 shs
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
$0.02
-8.0%
$0.85
$0.02
▼
$10.99
$363K1.1624.32 million shs121.84 million shs
Petros Pharmaceuticals, Inc. stock logo
PTPI
Petros Pharmaceuticals
$0.00
+15.4%
$0.00
$0.00
▼
$0.02
$93K2.04117,487 shs19,830 shs
10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CERo Therapeutics Holdings, Inc. stock logo
CERO
CERo Therapeutics
0.00%+41.18%-20.00%-57.52%-94.61%
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
0.00%-27.51%-38.95%-44.61%-56.65%
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
0.00%-70.86%-95.90%-99.12%-99.72%
Petros Pharmaceuticals, Inc. stock logo
PTPI
Petros Pharmaceuticals
0.00%-21.21%-3.70%-3.70%-84.34%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CERo Therapeutics Holdings, Inc. stock logo
CERO
CERo Therapeutics
2.00
HoldN/AN/A
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
1.00
SellN/AN/A
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
2.29
Hold$11.5071,775.00% Upside
Petros Pharmaceuticals, Inc. stock logo
PTPI
Petros Pharmaceuticals
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest PTPI, CNSP, KPTI, and CERO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/2/2026
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
DowngradeBuy ➝ Neutral
10/15/2026
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
Reiterated RatingSell (E+)
9/24/2026
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
DowngradeSell (D-) ➝ Sell (E+)
9/10/2026
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
UpgradeSell (E+) ➝ Sell (D-)
8/27/2026
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
DowngradeSell (D-) ➝ Sell (E+)
(Data available from 11/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CERo Therapeutics Holdings, Inc. stock logo
CERO
CERo Therapeutics
N/AN/AN/AN/A($41.98) per shareN/A
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
N/AN/AN/AN/A$7.29 per shareN/A
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
$146.07M0.00N/AN/A($16.00) per share0.00
Petros Pharmaceuticals, Inc. stock logo
PTPI
Petros Pharmaceuticals
$5.11M0.02N/AN/A$4.04 per share0.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CERo Therapeutics Holdings, Inc. stock logo
CERO
CERo Therapeutics
-$8.30M-$9.84N/AN/AN/AN/AN/A-209.40%12/2/2026 (Estimated)
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
-$15.85M-$23.59N/AN/AN/AN/A-204.25%-141.87%11/16/2026 (Estimated)
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
-$196.04M-$13.09N/AN/AN/A-153.28%N/A-145.18%N/A
Petros Pharmaceuticals, Inc. stock logo
PTPI
Petros Pharmaceuticals
-$8.16M-$0.36N/AN/AN/AN/A-78.22%-23.50%12/2/2026 (Estimated)

Latest PTPI, CNSP, KPTI, and CERO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/16/2026Q3 2026
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
-$0.27-$0.24+$0.03-$0.24N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
CERo Therapeutics Holdings, Inc. stock logo
CERO
CERo Therapeutics
N/AN/AN/AN/AN/A
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
N/AN/AN/AN/AN/A
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
N/AN/AN/AN/AN/A
Petros Pharmaceuticals, Inc. stock logo
PTPI
Petros Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CERo Therapeutics Holdings, Inc. stock logo
CERO
CERo Therapeutics
N/A
0.56
0.56
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
N/A
5.86
5.86
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
N/A
0.79
0.76
Petros Pharmaceuticals, Inc. stock logo
PTPI
Petros Pharmaceuticals
1.58
0.85
0.74

Institutional Ownership

CompanyInstitutional Ownership
CERo Therapeutics Holdings, Inc. stock logo
CERO
CERo Therapeutics
29.64%
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
14.02%
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
66.44%
Petros Pharmaceuticals, Inc. stock logo
PTPI
Petros Pharmaceuticals
12.34%
CompanyEmployeesShares OutstandingFree FloatOptionable
CERo Therapeutics Holdings, Inc. stock logo
CERO
CERo Therapeutics
871.63 million1.05 millionN/A
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
81.46 million1.43 millionNot Optionable
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
38022.68 million22.30 millionOptionable
Petros Pharmaceuticals, Inc. stock logo
PTPI
Petros Pharmaceuticals
2031.16 million9.93 millionNot Optionable

Recent News About These Companies

Petros Pharmaceuticals Delays Annual 10-K Filing
Petros Pharmaceuticals Inc (PTPI) - Investing.com
Petros Pharmaceuticals, Inc. (PTPI) - Yahoo Finance

New MarketBeat Followers Over Time

Media Sentiment Over Time

CERo Therapeutics stock logo

CERo Therapeutics NASDAQ:CERO

$0.0049 +0.00 (+2.08%)
As of 01:13 PM Eastern

CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.

CNS Pharmaceuticals stock logo

CNS Pharmaceuticals NASDAQ:CNSP

$3.28 +0.39 (+13.49%)
As of 02:07 PM Eastern
This is a fair market value price provided by Massive. Learn more.

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.

Karyopharm Therapeutics stock logo

Karyopharm Therapeutics NASDAQ:KPTI

$0.02 0.00 (-8.05%)
Closing price 11/10/2026
Extended Trading
$0.02 0.00 (0.00%)
As of 11/10/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Petros Pharmaceuticals stock logo

Petros Pharmaceuticals NASDAQ:PTPI

$0.0030 +0.00 (+15.38%)
As of 01:45 PM Eastern

Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, penile injections, PreBoost, VenoSeal, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York.